The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viruses (AAVs) have been used widely for in vivo gene therapy. However, adaptive immune responses to AAV have posed a significant hurdle in clinical application of AAV vectors. Recent advances have suggested a crucial role for innate immunity in shaping adaptive immune responses. How AAV activates innate immunity, and thereby promotes AAV-targeted adaptive immune responses, remains unknown. Here we show that AAV activates mouse plasmacytoid DCs (pDCs) via TLR9 to produce type I IFNs. In vivo, the TLR9-MyD88 pathway was crucial to the activation of CD8+ T cell responses to both the transgene product and the AAV capsid, leading to loss of transgene expression and the generation of transgene product-specific and AAV-neutralizing antibodies. We further demonstrate that TLR9-dependent activation of adaptive immunity targeting AAV was mediated by type I IFNs and that human pDCs could be activated in vitro to induce type I IFN production via TLR9. These results reveal an essential role for the TLR9-MyD88-type I IFN pathway in induction of adaptive immune responses to AAV and suggest that strategies that interfere with this pathway may improve the outcome of AAV-mediated gene therapy in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Myd88−/− mice that development of CD8+ T cell responses against rh32.33 capsid depended on MyD88(15, 17) (Fig. 2A, middle panel).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Tlr9−/− and Myd88−/− mice that the innate immune response to self-complementary AAV was indeed dependent on the TLR9/MyD88 pathway (Fig. 1D and 1E), as previously shown in the literature (15–17).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia are the chief resident immune cells of the retina and are capable of inducing pro-inflammatory cytokine expression through TLR9- and TLR2-mediated responses,41 which have been demonstrated to detect AAV genomes and capsids, respectively.42, 43, 44”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unmethylated CpG elements elicit innate immunity and CTL response through TLR9/MyD88-dependent pathway (23).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous animal studies have shown the immune-activating effects of CpG motifs in AAV (23, 150, 151).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Recognition of single-stranded RNA viruses by Toll-like receptor 7
Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,861
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W., & Schmitz, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6037 · Cited by 1,298
Cited by
Items 301–345 of 345
Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19 · Cited by 1
Even a Worm Will Turn: Immunity Following AAV Vector Administration
Patel, K., Khatri, A., & Somanathan, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_7
Preclinical development of viral vector gene therapies
Newman, M. S., Hudry, E., Brassard, J. A., & Cunningham, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00003-1
Caractérisation et immunomodulation de la réponse cellulaire contre les produits de thérapie génique
Avenel, A. (2024) · theses.fr (ABES) · doi:10.70675/f4cd9ee5z09e6z4e26z8edazf0770a51f57c
(2020) · Arizona State University Library Digital Repository (Arizona State University)
Preclinical Safety and Tolerability of an AAV Vector Expressing TLR9 in Mice and HamstersPreprint
Wootton, S. K., Yang, C., Santos, I., & Thompson, B. (2026) · Research Square · doi:10.21203/rs.3.rs-8545024/v1
Adeno-associated virus-induced neurotoxicity is prevented by CpG depletion
Dunn, C. E., Carvajal, B. V., Ma, J., Castaneda-Hernandez, G., Nguyen, A. V., Jung, C., Suriano, C. M., & Boulanger, L. M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201703 · Cited by 1
“7,8,27,28 Consistent with TLR9’s role in initiating transgene-limiting immune responses, reducing TLR9 activation is associated with more robust and persistent transgene expression.”
Les vecteurs AAV recombinants : un nouvel outil de vaccination contre les Hénipavirus
Ploquin, A. (2012) · theses.fr (ABES) · doi:10.70675/a11367cfzedd0z46bbz8125zcec139d25083
Carpentier, M. (2013) · theses.fr (ABES) · doi:10.70675/fa69ca30zf46az45f1z9638z003bd41555e4
Anchim, A. (2016) · theses.fr (ABES) · doi:10.70675/d10fb830z5afez4e17zb40fz3b23249344dc · Cited by 1
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Characterization of rAAV vectors packaging in baculovirusinfected insect cells
Penaud‐Budloo, M. (2018) · theses.fr (ABES) · doi:10.70675/c5cff6daz8fe4z430cz80e6z97a11cc59c8e
Sargent, D. (2018) · theses.fr (ABES) · doi:10.70675/2cd4ead6z0cd7z476dz8376z54bb3bd9a0ea
Bartolo, L. (2018) · theses.fr (ABES) · doi:10.70675/b32b9711za15dz4740z8481z0ba7dd36e8ee
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Inhibition du Virus de l’Hépatite Delta par des inducteurs de la voie NFκB
Chardès, B. (2019) · theses.fr (ABES) · doi:10.70675/1f17682fza956z4ba1za8c0za470231e90d4
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Ma, X., & Cepko, C. L. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.0869-26.2026
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783.1
abdelnaby, M., Galiakberova, A. A., & Dashinimaev, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156846
“Pattern recognition receptors, such as TLR9, TLR2, and MDA5/RIG-I, initiate innate immune responses upon detecting vector-associated molecular patterns [97,98].”
Jereb, S., D’Alessandro, L. R., Morshed, N., Chen, M., Sartore, R., Han, Z., McKinney, J. E., Brauer, P. P., Harvey, J. W., Demers, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.739854
“Toll-like receptor 9 (TLR9) signaling, induced by the presence of unmethylated CpG dinucleotides in AAV DNA (Hemmi et al., 2000), contributes to the immune response to AAV vectors (Zhu et al., 2009).”
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
“Unmethylated CpG motifs can be sensed by TLR9, leading to the production of type I interferon and subsequent activation of cytotoxic T Frontiers in Medicine 10 frontiersin.org lymphocytes (51, 52, 54, 146, 147).”
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
Asai, A., Aqul, A. A., Banc‐Husu, A. M., Diamond, T., Elisofon, S. A., Freeman, A. J., Loomes, K. M., Mohammad, S., Sundaram, S. S., & Chapin, C. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115317
Clinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848 · Cited by 1
“7,19 Additional preclinical studies have suggested potential contributions from AAV capsid recognition by TLR2 in human nonparenchymal liver cells and from cytosolic sensing of double-stranded RNA (dsRNA), potentially generated through bidirectional transcription from AAV ITRs, in human cell lines,…”
Zhang, X., Chang, A., Liu, Y., & Yu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1935135
Antioxidant Strategies for Inherited Retinal Degenerations in the Era of Gene Therapy
Yang, Y., Chen, Q., Zeng, J., Liang, L., Tao, Z., She, K., Ren, C., & Lu, F. (2026) · Antioxidants · doi:10.3390/antiox15101229
“In addition, unmethylated CpG motifs within inverted terminal repeats (ITRs) and transgene cassettes can activate TLR9–MyD88 signaling and type I interferon responses, further amplifying inflammatory signaling [63,69,70].”
Self-citationIn Vivo CAR T-cell Therapy: Determinants of Response and Durability
Abou‐El‐Enein, M. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0116
Ding, Q., Zhou, X., Olson, E. N., & Liu, N. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107709
Newman-Fogel, S. (2026) · QSpace (Queen's University Library)
Manz, J., Woernle, J., Hubbuch, J., Deepak, R., Noack, F., & Huellen, F. (2026) · Viruses · doi:10.3390/v18101158
“…administered gene therapies, as unmethylated CpGs are reported to act as pathogen-associated molecular patterns (PAMPs) that are recognized by TLR9, leading to a type I interferon response that can ultimately result in transgene silencing or immune-mediated clearance of transduced cells [14,15,28].”
Future directions and challenges of drug development and non-human primate models
Wang, Z., & Wu, X. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124768
Metadata
- Authors
- Zhu, J., Huang, X., & Yang, Y.
- Affiliations
- Duke Medical Center (US)
- Duke University (US)
- Corresponding author
- Yang, Yiping
- Venue
- Journal of Clinical Investigation
- Published
- 2009-08-03
- Volume
- 119
- Issue
- 8
- Pages
- 2388-2398
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2719948
- OpenAlex
- W2043149070
- Semantic Scholar
- 9808ef8c0218096852d97ab403f3e3a9feeb2215
- Cited by
- 330
- References
- 73
- Citations by year
- 2026: 23 · 2025: 20 · 2024: 26 · 2023: 31 · 2022: 29 · 2021: 27 · 2020: 29 · 2019: 24 · 2018: 16 · 2017: 17 · 2016: 7 · 2015: 15 · 2014: 10 · 2013: 15 · 2012: 11
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA047741)
- University of North Carolina at Chapel Hill
- National Cancer Institute (CA111807, CA047741, P01CA047741, R01CA111807)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV gene therapy, TLR9, MyD88, type I interferon, plasmacytoid dendritic cells, innate immunity, adaptive immune response, CD8+ T cells, AAV capsid, neutralizing antibodies, transgene expression, immunogenicity
- MeSH terms
- Dependovirus, Animals, Cells, Cultured, Dendritic Cells, Genetic Vectors, Humans, Immunity, Innate, Interferon Type I, Mice, Inbred BALB C, Mice, Inbred C57BL, Genetic Therapy, Signal Transduction, CD8-Positive T-Lymphocytes, Transgenes, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.